Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis.

Follow-up blood culture(s) Gram-negative bloodstream infections Mortality rate Persistent bacteraemia Risk score for persistent GN-BSI

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 23 12 2022
revised: 17 02 2023
accepted: 28 02 2023
medline: 22 8 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

The clinical usefulness of follow-up blood cultures (FUBCs) in gram-negative bloodstream infections (GN-BSIs) represents a debated issue. To assess the impact on the clinical outcome of FUBCs in patients with GN-BSI and to predict risk factors for persistent bacteraemia. PubMed-MEDLINE, Scopus, and the Cochrane Library Database were independently searched until 24 June, 2022. Randomized controlled trials, prospective, or retrospective observational studies, including patients affected by GN-BSIs. Primary endpoints were in-hospital mortality rate, and persistent blood stream infections were defined as FUBC-positive for the same pathogen isolated from index blood cultures (BCs). Hospitalized patients with documented GN-BSIs. Performance of FUBCs (defined as subsequent BCs collected at least 24 hours after index BCs). Quality of included studies was independently assessed according to the Cochrane Risk of Bias Tool and the Risk Of Bias In Non-randomized Studies of Interventions. Meta-analysis was performed by pooling odds ratio (OR) retrieved from studies providing adjustment for confounders using random-effect model with the inverse variance method. Risk factors for persistent blood stream infections were also assessed. A total of 3747 articles were screened, and 11 observational studies (6 assessing impact on outcome (N = 4631), and 5 investigating risk factors for persistent GN-BSI (N = 2566)), conducted between 2002 and 2020 were included. The execution of FUBCs was associated with a significantly lower risk of mortality (OR, 0.58; 95% CI, 0.49-0.70; I The execution of FUBCs is associated with a significantly low risk of mortality in patients with GN-BSIs. Our analysis could be useful to stratify patients at a high risk of persistent bacteraemia to optimize the use of FUBCs.

Sections du résumé

BACKGROUND BACKGROUND
The clinical usefulness of follow-up blood cultures (FUBCs) in gram-negative bloodstream infections (GN-BSIs) represents a debated issue.
OBJECTIVE OBJECTIVE
To assess the impact on the clinical outcome of FUBCs in patients with GN-BSI and to predict risk factors for persistent bacteraemia.
DATA SOURCES METHODS
PubMed-MEDLINE, Scopus, and the Cochrane Library Database were independently searched until 24 June, 2022.
STUDY ELIGIBILITY CRITERIA METHODS
Randomized controlled trials, prospective, or retrospective observational studies, including patients affected by GN-BSIs. Primary endpoints were in-hospital mortality rate, and persistent blood stream infections were defined as FUBC-positive for the same pathogen isolated from index blood cultures (BCs).
PARTICIPANTS METHODS
Hospitalized patients with documented GN-BSIs.
INTERVENTION METHODS
Performance of FUBCs (defined as subsequent BCs collected at least 24 hours after index BCs).
ASSESSMENT OF RISK OF BIAS UNASSIGNED
Quality of included studies was independently assessed according to the Cochrane Risk of Bias Tool and the Risk Of Bias In Non-randomized Studies of Interventions.
METHODS OF DATA SYNTHESIS UNASSIGNED
Meta-analysis was performed by pooling odds ratio (OR) retrieved from studies providing adjustment for confounders using random-effect model with the inverse variance method. Risk factors for persistent blood stream infections were also assessed.
RESULTS RESULTS
A total of 3747 articles were screened, and 11 observational studies (6 assessing impact on outcome (N = 4631), and 5 investigating risk factors for persistent GN-BSI (N = 2566)), conducted between 2002 and 2020 were included. The execution of FUBCs was associated with a significantly lower risk of mortality (OR, 0.58; 95% CI, 0.49-0.70; I
CONCLUSIONS CONCLUSIONS
The execution of FUBCs is associated with a significantly low risk of mortality in patients with GN-BSIs. Our analysis could be useful to stratify patients at a high risk of persistent bacteraemia to optimize the use of FUBCs.

Identifiants

pubmed: 36894053
pii: S1198-743X(23)00114-3
doi: 10.1016/j.cmi.2023.02.024
pii:
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1150-1158

Informations de copyright

Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Transparency declaration The authors declare that they have no conflicts of interest.

Auteurs

Milo Gatti (M)

Department of Medical and Surgical Sciences, University of Bologna, Italy; Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Cecilia Bonazzetti (C)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Beatrice Tazza (B)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Renato Pascale (R)

Department of Medical and Surgical Sciences, University of Bologna, Italy; Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Beatrice Miani (B)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Marta Malosso (M)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Giacomo Beci (G)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Domenico Marzolla (D)

Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Matteo Rinaldi (M)

Department of Medical and Surgical Sciences, University of Bologna, Italy; Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Pierluigi Viale (P)

Department of Medical and Surgical Sciences, University of Bologna, Italy; Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

Maddalena Giannella (M)

Department of Medical and Surgical Sciences, University of Bologna, Italy; Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy. Electronic address: maddalena.giannella@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH